Sarepta Therapeutics reports Q1 2026 results on May 6, and the setup heading in is tense: short interest is running near its highest level in months, a fresh spike in options defensiveness just appeared, and the most recent earnings print produced a painful double-digit drawdown.
The short-side pressure is substantial and has been building. Short interest on SRPT is now 27.1% of the free float — a level that puts this name in genuinely crowded territory. That figure climbed roughly 18% over the past month, rising from around 21% in late March to where it stands today. The week-on-week change is nearly flat (down half a percent), but the broader trend since mid-March has been one of consistent accumulation by shorts. Official FINRA data confirms the picture: 25.3 million shares short as of the April 15 settlement date, with days-to-cover running above 11. The lending market, however, is not being strained by this activity. Availability is extremely generous at roughly 796% of short interest — meaning there is far more stock available to borrow than is currently borrowed — and cost-to-borrow is just 0.46%, little changed from a month ago. That combination tells a specific story: shorts are positioned heavily, but the borrow market is not charging them for it. There is no squeeze pressure building in the lending pool.
Options are where the more interesting signal arrived this week. Tuesday's session saw the put/call ratio jump to 0.82 — more than three standard deviations above its 20-day average of 0.76. That is the sharpest defensive tilt the options market has registered in months, and it appeared in a single session rather than gradually. The 52-week range for the PCR runs from 0.34 to 1.04, so 0.82 is elevated but not at a record; what makes it notable is the speed of the move from a period of unusually stable options flow. The most likely explanation is traders buying protection ahead of the May 6 print.
The Street's position on Sarepta is visibly divided. Eight analysts carry buy ratings; twelve hold holds; and a vocal bear camp maintains sells — with HC Wainwright at a $5 target and Citigroup, which raised its sell-side target from $9 to $13 in late March, still well below the current $21 price. On the bull side, Oppenheimer holds an Outperform at $37 and Mizuho raised its target to $31 in mid-March. The consensus is a hold, with analyst return potential of around 3% — essentially flat from current levels when averaged across the full range of targets. Bulls lean on Sarepta's commercial execution around ELEVIDYS and expected milestone payments; bears focus on FDA uncertainty for the non-ambulatory patient indication, the company's lack of profitability, and the structural risks of a one-time gene therapy model limiting repeat revenue. The factor picture adds some nuance: EPS surprise ranks in the 96th percentile and 90-day EPS momentum is strong at the 81st percentile, suggesting the company has consistently outrun estimates. But 30-day EPS momentum has dropped to the 23rd percentile — a divergence worth noting ahead of the print. RSI-14 is a neutral 52.5, and the analyst rec diff factor ranks in the 97th percentile, reflecting the wide gap between the bearish consensus rating and what some of the more bullish houses are saying.
The last earnings event tells investors what the downside scenario looked like. On February 25, SRPT fell 7.4% on the day of the release and was down 14.6% five days later. That reaction happened even with the stock already in a weakened position. Heading into May 6 with SI at 27% of the float, elevated put demand, and a bull-bear divide that spans $32 of price-target distance — from $5 to $37 — the margin for error on guidance language and ELEVIDYS update commentary is narrow. Peers have had a rough week: CRBU dropped 7.6%, XGN fell 6.2%, and DYN slid 5.5%, while SRPT itself gained nearly 2% — a relative outperformance that underscores just how much positive expectation is already embedded in the name ahead of the announcement.
The May 6 print will focus attention on ELEVIDYS revenue trajectory, any update on the non-ambulatory FDA pathway, and whether near-term profitability milestones are holding on track — the factor driving the widest disagreement between the bulls and bears sitting on either side of this stock.
See the live data behind this article on ORTEX.
Open SRPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
